Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's Disease

Completed

Conditions: Parkinson Disease

Interventions: Drug: Pramipexole

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 442

Registration Number: NCT02248181

Efficacy and Safety of Talsaclidine (Free Base) in Patients With Mild to Moderate Dementia of Alzheimer Type

Phase 2

Terminated

Conditions: Alzheimer Disease

Interventions: Drug: Placebo
Drug: Talsaclidine

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 54

Registration Number: NCT02249351

Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)

Completed

Conditions: Restless Legs Syndrome

Interventions: Drug: Pramipexole

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1029

Registration Number: NCT02248142

Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease

Completed

Conditions: Parkinson Disease

Interventions: Drug: Pramipexole

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 657

Registration Number: NCT02248220

Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type

Phase 2

Terminated

Conditions: Alzheimer Disease

Interventions: Drug: Talsaclidine

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 198

Registration Number: NCT02248116

Antihypertensive Medications and the Risk of Sepsis

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan
Drug: Other angiotensin-receptor blockers (ARBs)
Drug: Angiotensin-converting enzyme inhibitors (ACEIs)
Drug: Other major antihypertensive medication classes

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1129062

Registration Number: NCT02248896

Pharmaco-epidemiological Study Describing a Population of Hypertensive Patients Treated With a Fixed-dose Combination of Telmisartan and Hydrochlorothiazide

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan and hydrochlorothiazide

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 4255

Registration Number: NCT02248129

Pharmacokinetics and Pharmacodynamics of BIWH 3 in Healthy Duffy Positive vs. Duffy Negative Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BIWH 3

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02249117

Effect of BIIL 284 BS on Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: BIIL 284 BS
Drug: Placebo

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 53

Registration Number: NCT02249338

Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type

Phase 2

Completed

Conditions: Alzheimer Disease

Interventions: Drug: Talsaclidine 36 mg
Drug: Talsaclidine 12 mg
Drug: Talsaclidine 6 mg
Drug: Talsaclidine 24 mg
Drug: Placebo

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 362

Registration Number: NCT02249403

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy